Division of Nephrology Clinical Studies

1 - 5 of 5

Genomics of Nephrotic Syndrome

For this study, we are studying the relationship between variations in the genes of the immune system called HLA and how they relate to:
  1. The risk of developing nephrotic syndrome
  2. The response to treatment of nephrotic syndrome and
  3. The risk of recurrence of nephrotic syndrome following kidney transplantation.
Participants will be asked to provide a one time blood sample for DNA testing and information about their health will be collected. 

To be eligible, participants must have:
  1. Clinical diagnosis of nephrotic syndrome
  2. Biopsy proven diagnosis of FSGS or MCD and,
  3. History of living or deceased donor kidney transplantation


CHOP is partnering with Children's National Medical Center (CNMC) to create a research database of data and blood samples of people who have autosomal polycystic kidney disease (ARPKD) or another hepato/renal fibrocystic disease (HRFD). The purpose is to try to learn more about the causes of these diseases. If you are interested in participating, we will collect data from your medical record to contribute to the database at CNMC. You may also provide an optional blood sample. You may visit arpkdb.org and download the FAQs for you and your child’s doctor or call the CHOP Research Coordinator, Mohini Dutt, at 267-425-3933.

Novel Imaging in Autosomal Recessive Polycystic Kidney Disease

In this study, we are developing new ultrasound and magnetic resonance imaging (MRI) methods to measure kidney and liver disease severity in autosomal recessive polycystic kidney disease (ARPKD). Participants in this study will include individuals with ARPKD, and a comparison group of healthy individuals without liver or kidney disease. Individuals of any age may take part in the study. 

MRI of ARPKD liver disease

The primary goal of this research study is to see if new types of magnetic resonance imaging (MRI) can be used to measure liver health in children with autosomal recessive polycystic kidney disease (ARPKD) compared to healthy controls.  Both children with ARPKD and healthy children, aged 6 years and above can participate.


The purpose of this NIH-funded placebo-controlled clinical trial is to determine how well ferric citrate will lower FGF23, correct anemia and iron levels in the blood, and maintain normal levels of phosphate in children with CKD. Chronic Kidney Disease (CKD) is a condition in which the kidney function is decreased. Fibroblast Growth Factor 23 (FGF23) is a hormone that regulates blood phosphate levels. High FGF23 levels are linked with worsening of kidney, bone & heart health. Ferric Citrate is an oral medication that decreases the absorption of dietary phosphate by the gut, lowers FGF23 levels and raises iron stores in the body. Ferric Citrate is approved in adults with CKD but has not yet been studied in children.

For more information visit www.fit4kidstudy.com